Multiplexed and quantitative immunolabelling for cancer diagnostics using gold-silver alloy nanoprobes

使用金银合金纳米探针进行癌症诊断的多重定量免疫标记

• 批准号: 571982-2022
• 负责人: Meunier, MichelM
• 金额: $ 9.11万
• 依托单位: École Polytechnique de Montréal
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=754571
• 关键词: Multiplexed; quantitative; immunolabelling; cancer; diagnostics

This proposal aims to introduce new immunolabelling probes based on gold-silver alloy nanoparticles (ANPs) for application in clinical pathology imaging of cancer. Such probes open the possibility to perform quantitative and multiplexed analysis, thus overcoming the important limitations of present immunolabelling techniques. These ANPs can be identified by their spectral signature (colour), enabling multiplexed cell labelling and identification. The ANP labels are stable and bright, and upon modification to bind a specific target, they can enable the biomarker quantification. Such quantification is highly valuable for pathologists who must precisely determine the cancer type and then select the most efficient treatment for the patient, as is needed for immunotherapy. We will mediate the maturation of our research to obtain a robust technology and demonstrate the advantages of antibody-functionalized ANPs as probes for the quantification of PD-L1, a protein biomarker of non-small cell lung cancer. Our approach ought to yield a much higher immunotherapy treatment success rate than is currently available by tailoring treatment specifically toward a patient. The target market segments for this technology are the reagents for immunolabelling (expected to reach USD $2.6 billion in 2026) and the global market for immunotherapy (USD $150 billion). A patent for our ANPs and related process has already been issued (US Patent 10,239,122 (2019)). Moreover, this project also shows potential for the development of new patents for the complete imaging system. Highly respected pathologists, who are potential users in the health sector, have confirmed the value of our new technology and will test it in their own clinical activities. To move our project to commercialization for the synthesis of ANPs, their functionalization, production of the optical imaging setup, and software analysis, the creation of a start-up at Polytechnique Montréal is being considered. Roche, an international leader in in vitro diagnostics, sees tremendous potential in this technology to transform cancer diagnosis and has expressed support for our PD-L1 detection strategy for partnership development.

该提案旨在引入基于金银合金纳米颗粒（ANP）的新型免疫标记探针，用于癌症的临床病理成像，此类探针为进行定量和多重分析提供了可能性，从而克服了现有免疫标记技术的重要局限性。可以通过其光谱特征（颜色）进行识别，从而实现多重细胞标记和识别。ANP 标记稳定且明亮，经过修饰以结合特定目标，它们可以启用生物标记物。这种定量对于病理学家来说非常有价值，他们必须精确确定癌症类型，然后为患者选择最有效的治疗方法，这是免疫疗法所需的，我们将促进我们的研究的成熟，以获得强大的技术并展示其优势。使用抗体功能化的 ANP 作为探针来定量 PD-L1（一种非小细胞肺癌的蛋白质生物标志物），我们的方法应该比目前专门针对患者定制治疗的方法产生更高的免疫治疗成功率。这该技术的目标市场领域是免疫标记试剂（预计到 2026 年将达到 26 亿美元）和全球免疫治疗市场（1,500 亿美元）。我们的 ANP 和相关工艺的专利已经获得（美国专利 10,239,122）。 2019））此外，该项目还显示了为完整成像系统开发新专利的潜力，他们是备受尊敬的病理学家，他们是该领域的潜在用户。卫生部门已经确认了我们新技术的价值，并将在他们自己的临床活动中对其进行测试，以将我们的项目推向商业化，用于合成 ANP、其功能化、光学成像装置的生产以及软件分析、创建。体外诊断领域的国际领导者罗氏正在考虑与蒙特利尔理工学院的一家初创公司合作，该公司看到了这项技术在改变癌症诊断方面的巨大潜力，并表示支持我们的合作伙伴关系发展的 PD-L1 检测策略。